Press Release

November 04, 2022

Evonik successfully renews €1.75 billion syndicated revolving credit facility

Essen, Germany. Evonik Industries AG has successfully refinanced its syndicated revolving credit facility with a core banking group of 16 banks. The new credit facility with an unchanged amount of €1.75 billion has a term of five years with two extension options of one year each and will end 2029 at the latest.

The credit facility represents the long-term liquidity reserve of the group and is currently not utilized. Based on its solid investment grade rating, Evonik was able to secure favorable terms. The facility continues to exclude financial covenants and secures financial flexibility as well as independence for the upcoming years.

Ute Wolf, Chief Financial Officer at Evonik, says: “The participation of 16 reputable banks confirms the banking sector’s trust in our growth strategy and underlines Evonik’s status as a long-term and reliable partner.”

The syndicate includes banks from the following countries: Germany (5), U.S. (3), Great Britain (2), France (2), Italy, Netherlands, Switzerland and China (1 each).

Mandated lead arrangers & bookrunners:

Bank of America, Bank of China, Barclays, BNP Paribas, Citi, Commerzbank, Credit Suisse, Deutsche Bank, DZ Bank, HSBC, ING, J.P. Morgan, Landesbank Baden-Württemberg, Landesbank Hessen-Thüringen, Société Générale, UniCredit.

The transaction was led by BNP Paribas and Commerzbank as coordinating banks.

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

Disclaimer

In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.